TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05732831: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic So

Sponsor: Tango Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 225 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$8,207,430

Rescue Site Savings

+$5,419,260

Unlock Full NCT05732831 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05732831 Rescue Dossier →